[go: up one dir, main page]

MX2019009586A - Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. - Google Patents

Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.

Info

Publication number
MX2019009586A
MX2019009586A MX2019009586A MX2019009586A MX2019009586A MX 2019009586 A MX2019009586 A MX 2019009586A MX 2019009586 A MX2019009586 A MX 2019009586A MX 2019009586 A MX2019009586 A MX 2019009586A MX 2019009586 A MX2019009586 A MX 2019009586A
Authority
MX
Mexico
Prior art keywords
permeability
compositions
methods
disease associated
treating disease
Prior art date
Application number
MX2019009586A
Other languages
English (en)
Inventor
Madan Jay
BLIKSLAGER Anthony
Original Assignee
Innovate Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovate Biopharmaceuticals Inc filed Critical Innovate Biopharmaceuticals Inc
Publication of MX2019009586A publication Critical patent/MX2019009586A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona métodos para tratar trastornos asociados con la disfunción de la barrera intestinal y el aumento de la permeabilidad intestinal. La invención implica administrar una cantidad eficaz de larazotide o un derivado de larazotide a un sujeto o paciente que lo necesite.
MX2019009586A 2017-02-10 2018-02-12 Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. MX2019009586A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762457279P 2017-02-10 2017-02-10
PCT/US2018/017813 WO2018148655A1 (en) 2017-02-10 2018-02-12 Compositions and methods for treating disease associated with permeability of intestinal epithelium

Publications (1)

Publication Number Publication Date
MX2019009586A true MX2019009586A (es) 2019-11-11

Family

ID=63107916

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009586A MX2019009586A (es) 2017-02-10 2018-02-12 Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.

Country Status (11)

Country Link
US (3) US20190358288A1 (es)
EP (2) EP3579863A4 (es)
JP (1) JP2020507626A (es)
KR (1) KR20190121785A (es)
CN (1) CN110891587A (es)
AU (1) AU2018219367A1 (es)
BR (1) BR112019016705A2 (es)
CA (1) CA3052975A1 (es)
MX (1) MX2019009586A (es)
WO (2) WO2018148654A1 (es)
ZA (1) ZA201905439B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020507626A (ja) * 2017-02-10 2020-03-12 イノベイト バイオファーマシューティカルズ インコーポレイテッド 腸上皮の透過性と関連する疾患を治療する組成物及び方法
WO2019165346A1 (en) 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Compounds and methods for treating tight junction permeability
US20210100868A1 (en) * 2018-03-19 2021-04-08 North Carolina State University Compositions and methods for treating or preventing gastrointestinal damage associated with nsaid therapy
US20210361734A1 (en) 2018-03-19 2021-11-25 9 Meters Biopharma, Inc. Compositions and methods for potentiating immune checkpoint inhibitor therapy
EP4013441A4 (en) * 2019-08-16 2023-08-30 9 Meters Biopharma, Inc. LARAZOTIDE FORMULATIONS
KR20230005209A (ko) * 2020-04-15 2023-01-09 9 미터스 바이오파마, 인코포레이티드 D-아미노산을 포함하는 라라조타이드 유도체
CN114788837B (zh) * 2022-06-07 2023-09-05 青岛东海药业有限公司 一种组合物及其在制备治疗和/或预防化疗引起的恶心呕吐的药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665389A (en) 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US5945510A (en) 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
ATE438405T1 (de) 2000-05-19 2009-08-15 Univ Maryland Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes
US20060062758A1 (en) * 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
US20090176244A1 (en) 2005-05-13 2009-07-09 Bai Julio Methods and compositions for the diagnosis of crohn's disease
JP2008545951A (ja) * 2005-05-13 2008-12-18 ユニバーシティ オブ メリーランド， ボルチモア ゾヌリンを決定することによる、処置養生法の有効性を評価するための方法
TW200716159A (en) * 2005-06-09 2007-05-01 Univ Maryland Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
EP1993357B1 (en) * 2006-02-09 2014-01-22 Alba Therapeutics Corporation Formulations for a tight junction effector
WO2008043107A2 (en) 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
US20110201543A1 (en) 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
WO2009015382A2 (en) 2007-07-26 2009-01-29 Alba Therapeutics Corporation Novel peptides that enhance tight junction permeability
WO2009052489A2 (en) 2007-10-19 2009-04-23 Alba Therapeutics Corporation Novel inhibitors of mammalian tight junction opening
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
CN101440369A (zh) * 2008-03-26 2009-05-27 华东师范大学 一种缺失的霍乱弧菌封闭带毒素的表达方法及应用
WO2009137572A2 (en) * 2008-05-06 2009-11-12 Alba Therapeutics Corporation Inhibition of gliadin peptides
US20110275566A1 (en) * 2008-10-10 2011-11-10 Nationwide Children's Hospital Inc. Methods of treating necrotizing enterocolitis using heparin binding epidermal growth factor (hb-egf)
EP3881830A1 (en) 2014-04-04 2021-09-22 Alba Therapeutics Corporation Methods of treating celiac disease with larazotide
CA2955425A1 (en) * 2014-07-17 2016-01-21 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
JP2020507626A (ja) * 2017-02-10 2020-03-12 イノベイト バイオファーマシューティカルズ インコーポレイテッド 腸上皮の透過性と関連する疾患を治療する組成物及び方法

Also Published As

Publication number Publication date
US11058902B2 (en) 2021-07-13
EP3579863A4 (en) 2020-11-11
WO2018148654A1 (en) 2018-08-16
EP3579862A4 (en) 2020-12-23
US20190358288A1 (en) 2019-11-28
JP2020507626A (ja) 2020-03-12
WO2018148655A1 (en) 2018-08-16
CA3052975A1 (en) 2018-08-16
ZA201905439B (en) 2021-02-24
US20190358289A1 (en) 2019-11-28
BR112019016705A2 (pt) 2020-04-07
EP3579863A1 (en) 2019-12-18
KR20190121785A (ko) 2019-10-28
EP3579862A1 (en) 2019-12-18
CN110891587A (zh) 2020-03-17
AU2018219367A1 (en) 2019-09-19
US20210299481A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2019009586A (es) Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
ZA201804513B (en) Method of treating c3 glomerulopathy
MX2017005875A (es) Metodos para tratar enfermedades oculares.
PH12015502773A1 (en) Methods for treating or preventing opthalmological conditions
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX388592B (es) Compuestos y metodos terapeuticos.
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
IL280952A (en) Methods and drug compounds for the treatment of ophthalmic diseases
MY205171A (en) Methods of treatment of hypertriglyceridemia
MX2017004723A (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX2019004200A (es) Terapia de combinacion.